Molgramostim (DB12525): A Comprehensive Monograph on a Novel Inhaled Therapy for Autoimmune Pulmonary Alveolar Proteinosis

Executive Summary

Molgramostim is an investigational biotech therapeutic poised to address a significant unmet medical need in the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare and debilitating lung disease. Developed by Savara Pharmaceuticals, Molgramostim is a recombinant, non-glycosylated form of human granulocyte-macrophage colony-stimulating factor (GM-CSF) formulated as an inhaled solution. Its mechanism of action directly targets the underlying pathophysiology of aPAP by restoring the function of alveolar macrophages, which are impaired by autoantibodies against endogenous GM-CSF. This targeted replacement therapy reactivates the natural clearance of lung surfactant, thereby improving pulmonary gas exchange.

The clinical development program has culminated in the pivotal Phase 3 IMPALA-2 trial, which demonstrated compelling and statistically significant efficacy across multiple domains. Treatment with inhaled Molgramostim resulted in marked improvements in pulmonary gas transfer, a key physiological measure of lung function. These objective gains were complemented by clinically meaningful enhancements in respiratory health-related quality of life and functional exercise capacity, directly linking the drug's physiological effect to tangible patient benefits. Furthermore, the therapy reduced the underlying surfactant burden in the lungs and decreased the need for whole lung lavage, the current invasive standard of care.

The safety profile of Molgramostim is generally favorable and well-tolerated, a characteristic largely attributable to its inhaled route of administration, which achieves high local drug concentrations in the lungs while minimizing systemic exposure. The low incidence of serious adverse events and minimal treatment discontinuation rates in clinical trials underscore its tolerability.

Despite the strength of its clinical data package, the path to market for Molgramostim has been impeded by a significant regulatory obstacle. In May 2025, the U.S. Food and Drug Administration (FDA) issued a Refuse to File (RTF) letter for the company's Biologics License Application (BLA), citing deficiencies in the Chemistry, Manufacturing, and Controls (CMC) data. This action, which did not raise concerns about the drug's clinical efficacy or safety, has shifted the primary risk of the program from the clinical to the technical and operational domain. The successful resolution of these manufacturing and quality control issues is now the critical determinant for regulatory approval.

Contingent on overcoming these CMC hurdles, Molgramostim is strongly positioned to become the first approved pharmacological therapy and the new standard of care for patients with aPAP, offering a non-invasive, disease-modifying treatment that could transform the management of this rare disease.

Section 1: Drug Profile and Physicochemical Characteristics

This section establishes the fundamental identity of Molgramostim, synthesizing all available data on its nomenclature, structure, and unique formulation as a drug-device combination product.

1.1. Identification and Nomenclature

Molgramostim is a well-characterized biopharmaceutical agent with multiple identifiers used across scientific literature, regulatory databases, and clinical development programs. A comprehensive understanding of its nomenclature is essential for tracking its history and development.

• Drug Name: Molgramostim [1]
• English Name: Molgramostim [User Query]
• DrugBank ID: DB12525 [User Query]
• Type: Biotech, Protein-Based Therapy [3]
• CAS Number: 99283-10-0 [4]
• Synonyms and Alternative Names: The drug has been referred to by numerous names throughout its development, reflecting its nature as a recombinant cytokine and its progression through different corporate and academic programs. These include: GM-CSF inhalation - Savara, Molgradex, Nebulised recombinant human GM-CSF - Savara, NPC 23, rh-GM-CSF, HUMAN MGI-1GM, HUMAN GM-CSF, HUMAN GRANULocyte MACROPHAGE COLONY STIMULATING FACTOR, HUMAN CSF-2, and HUMAN PLURIPOIETIN-ALPHA.[5] The intended brand name for the commercial product is MOLBREEVI.[5]
• Developer: The drug is currently being developed by Savara Pharmaceuticals. Its development history originates with Serendex Pharmaceuticals and includes foundational work at Justus Liebig University Giessen.[5]

1.2. Structural and Chemical Properties

Molgramostim is a protein therapeutic whose structure and properties are defined by its recombinant production method.

• Description: Molgramostim is a recombinant form of human granulocyte-macrophage colony-stimulating factor (GM-CSF).[1] A key distinguishing feature is that it is non-glycosylated, a direct result of its production in a bacterial expression system.[8] This differentiates it from other recombinant GM-CSF products, such as Sargramostim, which are produced in yeast and are glycosylated.
• Molecular Formula and Weight: As a large protein, its molecular formula and weight are substantial. The most frequently cited formula is C639​H1007​N171​O196​S8​, with a corresponding molecular weight of approximately 14477.38 Da.[10] The average molecular weight is consistently reported in this range, providing a reliable identifier for the molecule.[10]
• Amino Acid Sequence: Molgramostim is a polypeptide consisting of 127 amino acids.[11] A characteristic feature of its production in Escherichia coli is the presence of an additional N-terminal methionine residue, which is not present in the native human protein.[13] The full amino acid sequence is as follows [11]:

APARSPSPST QPWEHVNAIQ EARRLLNLSR DTAAEMNETV EVISEMFDLQ EPTCLQTRLE LYKQGLRGSL TKLKGPLTMM ASHYKQHCPP TPETSCATQI ITFESFKENL KDFLLVIPFD CWEPVQE

• Physical Form: In its purified form, Molgramostim is a white to off-white lyophilized powder that is soluble in water.[6] For clinical use, it is formulated into a sterile liquid solution.

1.3. Formulation and Delivery System

The therapeutic strategy for Molgramostim is intrinsically linked to its specialized formulation and delivery device, which together constitute a drug-device combination product. This integration is crucial for achieving targeted delivery to the lungs while minimizing systemic side effects.

• Formulation: Molgramostim is formulated as a sterile nebulizer solution intended for inhalation.[8] The standard clinical formulation used in pivotal trials contains 300 µg of Molgramostim in a 1.2 mL solution, resulting in a concentration of 250 µg/mL.[8]
• Excipients: To ensure the stability and appropriate aerosol properties of the protein therapeutic, the formulation includes several excipients: mannitol, polyethylene glycol 4000 (PEG 4000), recombinant human albumin (for protein stabilization), disodium phosphate, citric acid, and water for injection.[14]
• Delivery Device: Administration is performed using a specific, investigational eFlow® Nebulizer System developed by PARI Pharma GmbH.[8] This device is not an incidental component but has been optimized to work with the Molgramostim formulation to ensure consistent and efficient drug delivery.
• Aerosol Characteristics: The drug-device combination is engineered to produce an aerosol with specific properties ideal for deep lung deposition. Laser diffraction studies have shown that the nebulizer generates particles with a Mass Median Diameter of 3.5 µm. This results in a high respirable fraction, with 76.9% of particles being smaller than 5 µm, the optimal size range for reaching the alveoli.[15]

The nature of Molgramostim as a drug-device combination product has profound implications. The regulatory review and manufacturing requirements extend beyond the biologic agent itself to encompass the nebulizer device and the interaction between the two. The Chemistry, Manufacturing, and Controls (CMC) data required for approval must validate not only the purity and consistency of the protein but also the performance, reliability, and quality of the device, as well as the stability and delivery characteristics of the final combination. This complexity adds significant layers to the manufacturing validation and quality control processes and may have been a contributing factor to the CMC deficiencies identified by the FDA.

Table 1: Molgramostim Drug Identification and Key Properties
Identifier	Value	Source(s)
DrugBank ID	DB12525	[User Query]
CAS Number	99283-10-0	4
Type	Biotech, Protein-Based Therapy	3
Intended Brand Name	MOLBREEVI	5
Molecular Formula	C639​H1007​N171​O196​S8​	10
Average Molecular Weight	~14.477 kDa	10
Amino Acid Length	127 (+ N-terminal Methionine)	11
Formulation	Sterile Nebulizer Solution (300 µg / 1.2 mL)	8
Delivery System	eFlow® Nebulizer System (PARI Pharma GmbH)	8

Section 2: Preclinical and Clinical Pharmacology

This section provides a deep dive into how Molgramostim works, from its molecular interactions to its absorption, distribution, metabolism, and excretion (ADME) profile, and its ultimate biological effects.

2.1. Mechanism of Action

The therapeutic effect of Molgramostim is rooted in its function as a replacement for endogenous GM-CSF, directly correcting the central pathological defect in autoimmune Pulmonary Alveolar Proteinosis (aPAP).

• Core Mechanism: As a recombinant human GM-CSF, Molgramostim is a cytokine that plays a crucial role in the hematopoietic system and immune function.[16] It exerts its effects by binding to specific GM-CSF receptors on the surface of various cells, most notably hematopoietic progenitor cells and mature myeloid cells such as macrophages, neutrophils, and dendritic cells.[16] This binding initiates a signaling cascade that modulates the proliferation, differentiation, and activation of these target cells.[16]
• Action in aPAP: The pathophysiology of aPAP is defined by the presence of neutralizing autoantibodies that target and inactivate the body's own GM-CSF.[8] This disruption of GM-CSF signaling is particularly consequential in the lungs, where alveolar macrophages require a constant GM-CSF signal to perform their critical function of catabolizing and clearing pulmonary surfactant.[19] Without this signal, macrophages become dysfunctional, leading to the massive accumulation of surfactant within the alveoli.[8] Molgramostim, delivered directly to the lungs via inhalation, acts as a potent replacement therapy. The high local concentration of the drug overwhelms the neutralizing capacity of the autoantibodies, effectively restoring the GM-CSF signal to the alveolar macrophages.[1]
• Therapeutic Outcome: The restoration of GM-CSF signaling reactivates the alveolar macrophages, enabling them to resume their surfactant clearance duties.[1] This leads to a reduction in the pathological surfactant burden, which in turn alleviates the primary consequences of the disease: the physical obstruction of the alveoli is reduced, lung stiffness decreases, and the barrier to gas exchange is thinned. The ultimate result is an improvement in the transfer of oxygen from the inhaled air into the bloodstream, leading to better overall oxygenation and a reduction in symptoms like dyspnea.[1]
• Broader Immunomodulatory Effects: While its action in aPAP is highly specific, GM-CSF has broader effects on the immune system. It stimulates the production and function of neutrophils and dendritic cells, enhances antigen presentation, and can upregulate antibody-dependent cellular cytotoxicity (ADCC).[16] These immunostimulatory properties provide the scientific rationale for its investigation in other conditions, such as chronic infections where enhancing macrophage activity could be beneficial.

2.2. Pharmacokinetics (ADME)

The pharmacokinetic profile of inhaled Molgramostim was characterized in a pivotal Phase 1 clinical trial involving 42 healthy adult volunteers. The study included both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts and revealed a profile optimized for local efficacy and systemic safety.[23]

• Absorption: Following administration via nebulizer, Molgramostim is rapidly absorbed from the lungs into the systemic circulation. Measurable serum concentrations were detected as early as 30 minutes post-inhalation. The time to reach peak serum concentration (Tmax​) was consistently observed at approximately 2 hours across all tested single doses (150 µg, 300 µg, and 600 µg).[14]
• Distribution and Systemic Exposure: A critical finding of the Phase 1 study is that despite rapid absorption, the overall systemic exposure to Molgramostim is very low, with serum concentrations described as being at "picogram levels".[23] This indicates that the majority of the inhaled dose remains localized within the lungs to exert its therapeutic effect, with only a small fraction entering the bloodstream. The systemic exposure was found to be non-linear. For example, in the SAD study, a two-fold dose increase from 150 µg to 300 µg resulted in a greater than four-fold increase in peak concentration ( Cmax​), while a subsequent two-fold increase to 600 µg resulted in a less-than-proportional increase, indicating complex absorption and clearance dynamics.[23]
• Metabolism: As a protein therapeutic, Molgramostim is presumed to be metabolized through catabolic pathways, where it is broken down into smaller peptides and constituent amino acids by proteases throughout the body. Specific metabolic studies have not been detailed in the available materials.
• Elimination: The drug is cleared from the systemic circulation relatively quickly. The elimination half-life (t1/2​) was observed to be dose-dependent, ranging from approximately 1.7 hours at lower doses to up to 5.9 hours at the highest single dose of 600 µg.[23]

2.3. Pharmacodynamics

The pharmacodynamic effects of Molgramostim, or the biological response to the drug, were also assessed in the Phase 1 trial and are consistent with the known activity of GM-CSF.

• Leukocyte Response: Inhaled Molgramostim produced a rapid and dose-dependent increase in the number of circulating white blood cells (WBCs), particularly affecting leukocyte subsets such as neutrophils and monocytes.[23] This systemic biological response confirms that even the low picogram levels of drug reaching the circulation are pharmacologically active.
• Transient Effect: Importantly, this effect on WBC counts was transient. In the SAD study, leukocyte counts returned to baseline within 8 hours. Following multiple daily doses in the MAD study, counts normalized within 15 to 21 days after the final dose.[23] A key safety finding was that these transient increases in WBCs largely remained within the normal clinical reference ranges, suggesting that the low systemic exposure does not lead to excessive or pathological hematopoietic stimulation.[17]
• Antibody Formation: A crucial assessment for any protein therapeutic is its potential immunogenicity. In the Phase 1 trial, there was no evidence of anti-drug antibody formation against Molgramostim.[23]

The pharmacological profile of inhaled Molgramostim is exceptionally well-suited for its intended indication. The inhaled route of administration successfully delivers the drug directly to the alveolar macrophages, the site of pathology in aPAP. This strategy achieves a high local concentration necessary to overcome the neutralizing autoantibodies and restore macrophage function, thereby maximizing therapeutic efficacy. Concurrently, the pharmacokinetic data confirm that systemic exposure is minimal. This low systemic exposure is a key safety feature, as it leads to only transient and clinically insignificant pharmacodynamic effects on peripheral blood counts, thereby avoiding the potential for more severe systemic side effects that could be associated with systemically administered GM-CSF. This creates a highly favorable therapeutic window, maximizing local benefit while minimizing systemic risk, which is a cornerstone of the drug's value proposition.

Table 2: Summary of Pharmacokinetic Parameters of Inhaled Molgramostim in Healthy Volunteers
Parameter	Dose	Study Type	Value	Source(s)
Time to Peak Concentration (Tmax​)	150, 300, 600 µg	SAD	~2 hours	23
Peak Serum Concentration (Cmax​)	150 µg	SAD	9.1 pg/mL	23
	300 µg	SAD	40.7 pg/mL	23
	600 µg	SAD	34.1 pg/mL	23
Elimination Half-Life (t1/2​)	150-600 µg	SAD & MAD	1.7 to 5.9 hours	23
Systemic Exposure Profile	All doses	SAD & MAD	Non-linear; picogram levels	23

Section 3: Clinical Development for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

This section forms the core of the report, providing a comprehensive analysis of the clinical trial program that establishes Molgramostim's efficacy and safety in its primary indication.

3.1. Pathophysiology of aPAP and Rationale for GM-CSF Therapy

• Disease Overview: Autoimmune Pulmonary Alveolar Proteinosis (aPAP) is a rare autoimmune lung disease driven by the development of polyclonal, high-affinity immunoglobulin G (IgG) autoantibodies that bind to and neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF).[8] This neutralization prevents GM-CSF from signaling to its primary target cells in the lung, the alveolar macrophages. Consequently, these macrophages fail to mature properly and cannot perform their essential function of clearing surfactant—an oily substance that lines the alveoli.[19] The resulting accumulation of lipoproteinaceous material within the air sacs physically obstructs the alveoli, increases lung stiffness, and creates a significant barrier to gas exchange.[19]
• Clinical Manifestations: Patients with aPAP typically present with progressive exertional dyspnea (shortness of breath), a persistent and often debilitating cough, and overwhelming fatigue.[8] The disease impairs quality of life and increases the risk of opportunistic pulmonary infections. In its more severe forms, aPAP can progress to cause pulmonary fibrosis, chronic respiratory failure requiring long-term oxygen therapy, and may ultimately necessitate a lung transplant.[8]
• Standard of Care: To date, no pharmacological therapy has been approved for aPAP. The established standard of care is Whole Lung Lavage (WLL), a highly invasive procedure performed under general anesthesia where one lung is repeatedly filled with warmed saline and drained to physically wash out the accumulated surfactant.[19] While effective at temporarily relieving symptoms, WLL does not address the underlying autoimmune pathology and must be repeated as surfactant re-accumulates. The procedure carries significant risks, including damage to the airway, lung collapse, infection, and complications from anesthesia, and is only available at a limited number of specialized centers.[8] This creates a profound unmet medical need for a safe, effective, and non-invasive treatment that can be administered chronically to manage the disease.[8]
• Therapeutic Rationale: The therapeutic rationale for Molgramostim is elegant in its directness. By delivering an excess of recombinant GM-CSF via inhalation directly to the lungs, the therapy aims to saturate and overwhelm the neutralizing autoantibodies present in the alveolar space. This provides a sufficient concentration of active GM-CSF to bind to macrophage receptors and restore the signaling required for surfactant catabolism, thereby correcting the fundamental biological defect of the disease.[8]

3.2. The Pivotal IMPALA-2 Phase 3 Trial: A Definitive Analysis

The IMPALA-2 trial stands as the largest and most robust clinical investigation ever conducted in aPAP, providing definitive evidence of Molgramostim's efficacy and safety.

3.2.1. Study Design and Methodology

IMPALA-2 was a global, pivotal, Phase 3, randomized, double-blind, placebo-controlled clinical trial designed to confirm the efficacy and safety of inhaled Molgramostim.[21] A total of 164 adult patients with a confirmed diagnosis of aPAP were enrolled and randomized in a 1:1 ratio to receive either 300 µg of Molgramostim nebulizer solution or a matching placebo, self-administered once daily for a 48-week treatment period.[27] The trial was designed with a primary efficacy assessment at Week 24 to evaluate the initial treatment effect, with continued assessment through Week 48 to establish the durability of the response.[26]

3.2.2. Primary and Secondary Efficacy Endpoints

The trial successfully met its primary and multiple key secondary endpoints, demonstrating a consistent and clinically meaningful benefit.

• Primary Endpoint: Change in DLco% at Week 24: The primary endpoint was the change from baseline in the hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide (DLco%), a standard physiological measure of the lungs' ability to transfer gas into the bloodstream. The trial achieved this endpoint with high statistical significance. Patients in the Molgramostim group experienced a mean improvement of 9.8% from baseline, compared to just 3.8% in the placebo group. This resulted in an estimated treatment difference of 6.0% (p<0.001), indicating a substantial improvement in pulmonary gas exchange.[26]
• Durability of Effect (DLco% at Week 48): The therapeutic benefit was not only maintained but also appeared to increase over time. At the 48-week mark, the mean improvement from baseline in the Molgramostim group was 11.6%, versus 4.7% for placebo. The treatment difference widened to 6.9% (p<0.001), demonstrating a durable and sustained effect on lung function.[26] The magnitude of this improvement approaches the 10% threshold often considered a minimal clinically meaningful difference in other lung diseases like pulmonary fibrosis.[26]
• Patient-Reported Outcomes (SGRQ): Treatment with Molgramostim translated into a significant improvement in patients' perception of their own health. This was measured by the St. George's Respiratory Questionnaire (SGRQ), a validated tool for assessing respiratory health-related quality of life. At Week 24, the SGRQ Total Score improved by a mean of -11.5 points in the Molgramostim group, compared to -4.9 points for placebo. The treatment difference of -6.6 points was statistically significant (p=0.007) and exceeded the 4-point threshold for a clinically meaningful improvement.[20]
• Functional Improvement (Exercise Capacity): The physiological and quality-of-life improvements were accompanied by enhanced functional capacity. Exercise capacity, measured in peak metabolic equivalents (METs) achieved during a treadmill test, showed a greater improvement in the Molgramostim group. At Week 48, the treatment difference was 0.6 METs, an increase considered clinically useful in the context of cardiovascular rehabilitation and prognosis.[26]

3.2.3. Exploratory Endpoints and Clinical Impact

Further analyses provided objective evidence of the drug's mechanism and its impact on clinical management.

• Surfactant Burden (GGO Score): An exploratory endpoint assessed the change in surfactant burden using a ground glass opacity (GGO) score derived from chest CT scans. Molgramostim led to a significantly greater reduction in GGO score compared to placebo at Week 24 (mean reduction of -2.1 points vs. -1.1 points; p=0.0004).[21] This provides direct radiological evidence that Molgramostim is effectively clearing the accumulated surfactant from the lungs, confirming its mechanism of action.
• Reduction in Need for WLL: Perhaps one of the most clinically relevant outcomes was the impact on the need for rescue therapy. Over the 48-week trial period, a smaller proportion of patients in the Molgramostim group required a WLL (6 patients, 7.4%) compared to the placebo group (11 patients, 13.3%).[21] This demonstrates a tangible clinical benefit by reducing the need for an invasive, high-risk procedure.

3.3. Supporting Evidence from the IMPALA Program

The robust design of the IMPALA-2 trial was informed by the findings of the preceding Phase 2/3 IMPALA trial (MOL-PAP-002).[29] This earlier study explored both a once-daily 300 µg dosing regimen and an intermittent regimen (300 µg daily for 7 days, followed by 7 days off).[31] The results clearly indicated that the therapeutic effect was dose-frequency dependent, with the continuous once-daily regimen demonstrating superior efficacy compared to both the intermittent regimen and placebo.[19] This crucial learning provided a strong rationale for selecting the 300 µg once-daily dose for the confirmatory IMPALA-2 study, reflecting a logical and data-driven approach to clinical development.

The results of the IMPALA-2 trial present a remarkably coherent and powerful case for the efficacy of Molgramostim. There is a clear and logical cascade of evidence that connects the drug's fundamental mechanism to clinically meaningful outcomes. The therapy is designed to clear surfactant, and radiological imaging confirms that it reduces surfactant burden (GGO score). This reduction in surfactant improves the lung's ability to function, as demonstrated by the significant improvement in gas transfer (DLco%). Improved lung function makes breathing easier for patients, which is reflected in their substantially improved quality of life scores (SGRQ). When patients can breathe better, they can be more active, as shown by the increase in exercise capacity (peak METs). Finally, by controlling the underlying disease process, the therapy reduces the need for invasive rescue procedures (WLL). This complete and consistent chain of evidence, from molecular mechanism to patient-centric benefit, makes the clinical data package exceptionally robust and persuasive.

Table 3: Key Efficacy Outcomes of the IMPALA-2 Phase 3 Trial
Endpoint	Timepoint	Molgramostim Group	Placebo Group	Treatment Difference	P-value
Change in DLco% (%)	Week 24	+9.8	+3.8	6.0	<0.001
Change in DLco% (%)	Week 48	+11.6	+4.7	6.9	<0.001
Change in SGRQ Total Score	Week 24	-11.5	-4.9	-6.6	0.007
Change in Peak METs	Week 48	+1.1	+0.6	0.6	-
Change in GGO Score	Week 24	-2.1	-1.1	-1.0	0.0004
Patients Requiring WLL (%)	Week 48	7.4	13.3	-5.9	-
Sources: 20

Section 4: Investigational Use in Other Indications

This section provides context on the broader development program, highlighting both the specificity of Molgramostim's effect and the strategic focus of the developer.

4.1. Nontuberculous Mycobacterial (NTM) Infection

The immunomodulatory properties of GM-CSF, particularly its ability to activate macrophages, provided a strong rationale for investigating Molgramostim as an adjunctive therapy for chronic pulmonary infections caused by nontuberculous mycobacteria (NTM).[32]

• OPTIMA Trial: A Phase 2a open-label pilot trial, known as OPTIMA (NCT03421743), was conducted to evaluate the efficacy and safety of once-daily inhaled Molgramostim in patients with treatment-refractory pulmonary NTM infections, focusing on the two most common causative organisms, Mycobacterium avium complex (MAC) and M. abscessus (MABS).[2]
• Efficacy: The trial demonstrated a modest but encouraging signal of efficacy, particularly in the MAC cohort. Sputum culture conversion (the primary goal of NTM therapy) was achieved in 29.2% of patients with MAC infection during treatment. This rate is considered favorable when compared to historical outcomes for this highly refractory patient population managed with standard antibiotic therapy alone. However, the benefit observed in patients with MABS infection was less pronounced.[32]
• Safety: In this population of patients with severe, chronic lung disease, Molgramostim was found to be safe and well-tolerated, with no new safety concerns identified.[32]
• Status: While the results suggest potential utility, particularly for MAC infections, this remains an investigational use. The primary development focus for Savara Pharmaceuticals is squarely on the aPAP indication.

4.2. Discontinued and Early-Phase Programs

Over its development history, Molgramostim has been evaluated in several other respiratory conditions, reflecting an initial exploration of its broader potential.

• Discontinued Programs: Clinical development has been officially discontinued for the indications of bronchiectasis and cystic fibrosis.[3]
• Early-Phase Programs: Phase 2 clinical trials have been conducted to assess the potential of Molgramostim in treating Adult Respiratory Distress Syndrome (ARDS) and SARS-CoV-2 acute respiratory disease, conditions where modulating the pulmonary immune response could be beneficial.[5]
• Strategic Shift: The evolution of the clinical program reflects a significant strategic realignment by the developer. In 2020, Savara Pharmaceuticals undertook a major pipeline restructuring, discontinuing other assets to concentrate its resources and expertise almost exclusively on advancing the Molgramostim program for aPAP.[7]

The broader clinical development history of Molgramostim reveals a strategic journey from exploring its utility across a range of respiratory diseases to a highly focused pursuit of a single orphan indication. The initial investigations in conditions like NTM, bronchiectasis, and ARDS were based on the plausible hypothesis that enhancing local macrophage function could be broadly beneficial. However, the clinical signals in these areas were either modest or did not warrant further investment. In stark contrast, the therapeutic rationale for Molgramostim in aPAP is not just plausible but is a direct correction of the disease's core pathophysiology—a true replacement therapy for a defined GM-CSF deficiency. The company astutely recognized that its asset was not a pan-respiratory drug but a precision therapy for a specific, well-defined disease. This strategic pivot to focus exclusively on aPAP, where the drug's mechanism is perfectly aligned with the pathology, dramatically increased the probability of clinical and regulatory success for that indication. This classic orphan drug development strategy clarifies the drug's primary value proposition and defines the boundaries of its market opportunity.

Section 5: Comprehensive Safety and Tolerability Profile

This section will consolidate all available safety data to provide a holistic view of Molgramostim's risk profile, including adverse events, drug interactions, and contraindications.

5.1. Analysis of Adverse Events from Clinical Trials

Across its extensive clinical development program, including Phase 1 studies in healthy volunteers and Phase 2/3 trials in patients with aPAP and NTM, Molgramostim has consistently demonstrated a favorable safety and tolerability profile.[23]

• Overall Profile: The therapy is generally described as well-tolerated.[20] The majority of adverse events reported have been mild to moderate in severity.[33]
• Common Treatment-Emergent Adverse Events (TEAEs): The most frequently reported TEAEs are consistent with what might be expected from an inhaled therapy and the underlying respiratory conditions being studied. These commonly include cough, nasopharyngitis (the common cold), upper respiratory tract infection, pyrexia (fever), headache, and dyspnea (shortness of breath).[19] In the pivotal IMPALA-2 trial, the overall frequency of adverse events was generally similar between the Molgramostim and placebo groups, suggesting a favorable side-effect profile.[20] In some earlier trials, chest pain was noted to occur more frequently in patients receiving Molgramostim compared to placebo.[19]

5.2. Serious Adverse Events and Discontinuation Rates

The rates of more severe events and treatment discontinuations provide strong evidence of the drug's tolerability.

• Serious Adverse Events (SAEs): The incidence of SAEs in clinical trials has been consistently low. Crucially, the majority of reported SAEs have been judged by investigators to be unrelated to the study drug, and are often related to the progression of the underlying disease or intercurrent illnesses.[32] For instance, in a long-term safety study, reported SAEs included worsening of alveolar proteinosis, respiratory failure, and various infections, none of which were attributed to Molgramostim treatment.[33]
• Discontinuation Rates: The rate at which patients stop treatment due to side effects is a robust indicator of a drug's tolerability. For Molgramostim, this rate has been exceptionally low. In the large, 48-week IMPALA-2 trial, only two patients (2.5%) in the Molgramostim arm discontinued treatment due to an adverse event, and both of these events were considered unrelated to the drug.[20] Similarly, in a long-term open-label extension study, no patients discontinued the drug due to a treatment-emergent adverse event.[33]

The overall safety profile provides strong support for the therapeutic strategy of local, inhaled administration. The pharmacokinetic data show that this approach leads to minimal systemic drug exposure, and the clinical safety data confirm the benefit of this approach. The most common adverse events, such as cough, are likely related to the local effects of aerosol inhalation rather than systemic pharmacology. The lack of significant systemic side effects, coupled with the extremely low rates of discontinuation, indicates that the inhaled route successfully mitigates the risks that would be associated with higher-dose, systemic administration of a potent cytokine like GM-CSF. This results in a highly favorable benefit-risk assessment from a clinical safety perspective.

Table 4: Summary of Common Treatment-Emergent Adverse Events (TEAEs) in aPAP Clinical Trials
Adverse Event	Frequency in Molgramostim Group (%)	Frequency in Placebo Group (%)	Severity (Typically)
Cough	13.6 - 26.7	0	Mild/Moderate
Nasopharyngitis	4.5 - 13.3	18.2	Mild/Moderate
Respiratory Tract Infection	4.5 - 20.0	0	Mild/Moderate
Arthralgia (Joint Pain)	4.5 - 20.0	0	Mild/Moderate
Dyspnea	4.5 - 13.3	0	Mild/Moderate
Fatigue	0 - 13.3	4.5	Mild/Moderate
Note: Frequencies are compiled from long-term safety data and may vary between trials. Sources: 20

5.3. Drug Interactions and Contraindications

While a formal drug label is not yet available, data from pharmacology databases and clinical trial exclusion criteria provide insight into potential drug interactions and populations where caution is warranted.

• Drug Interactions:
• Methemoglobinemia: A significant number of potential drug interactions have been identified that may increase the risk or severity of methemoglobinemia, a condition where hemoglobin is unable to release oxygen effectively. This risk is elevated when Molgramostim is combined with a wide range of drugs, most notably local anesthetics (e.g., benzocaine, lidocaine, bupivacaine, ropivacaine) and other compounds such as capsaicin, diphenhydramine, and phenol.[3]
• Thrombosis: Consistent with the known class effects of hematopoietic growth factors, the risk or severity of thrombosis (blood clot formation) may be increased when Molgramostim is used concomitantly with erythropoiesis-stimulating agents like erythropoietin, darbepoetin alfa, and peginesatide.[3]
• Contraindications and Exclusion Criteria: The exclusion criteria used in the pivotal clinical trials serve as a de facto list of contraindications. Patients with the following conditions were typically excluded and should be considered with caution for treatment:
• A known history of allergic reactions or hypersensitivity to GM-CSF or any of the formulation's excipients.[31]
• A history of or a current diagnosis of a myeloproliferative disease or leukemia, due to the growth-factor nature of GM-CSF.[31]
• Concurrent use of significant immunosuppressive therapy (e.g., systemic prednisolone at doses greater than 10 mg/day).[31]
• Pregnancy or breastfeeding.[9]
• A diagnosis of hereditary or secondary PAP, as the underlying pathophysiology of these conditions is different from autoimmune PAP and would not be expected to respond to GM-CSF replacement.[8]

Table 5: Known and Potential Drug Interactions with Molgramostim
Interacting Drug/Class	Potential Risk	Source(s)
Local Anesthetics (e.g., Benzocaine, Lidocaine, Bupivacaine)	Increased risk or severity of Methemoglobinemia	3
Other Agents (e.g., Capsaicin, Diphenhydramine, Phenol)	Increased risk or severity of Methemoglobinemia	3
Erythropoiesis-Stimulating Agents (e.g., Erythropoietin)	Increased risk or severity of Thrombosis	3

Section 6: Manufacturing, Formulation, and Delivery

This section addresses the most critical current issue in Molgramostim's development: its manufacturing and the associated regulatory challenges.

6.1. Recombinant Protein Production

The production of Molgramostim utilizes well-established and cost-effective biotechnology methods for generating recombinant proteins.

• Expression System: Molgramostim is produced using an Escherichia coli bacterial expression system.[8] This method involves introducing a plasmid containing the genetically engineered gene for human GM-CSF into a suitable E. coli host strain.[15]
• General Process: The general workflow for this type of recombinant protein production is a multi-step process. First, the target gene is cloned into an expression vector, which is then transformed into the E. coli host cells.[38] The bacterial culture is grown to a high density, at which point protein expression is induced, often through the addition of an agent like IPTG.[38] This triggers the bacterial machinery to produce large quantities of the target protein. After a period of expression, the cells are harvested and lysed to release the protein. The final step involves a series of purification techniques, such as affinity chromatography, to isolate the pure, active Molgramostim protein.[38] A key consequence of this bacterial production method is that the resulting protein is non-glycosylated, as E. coli lacks the cellular machinery for this type of post-translational modification.[13]

6.2. Chemistry, Manufacturing, and Controls (CMC) Challenges

Despite the strength of its clinical data, the Molgramostim program encountered a major setback related to its manufacturing processes, which has become the primary obstacle to its approval.

• The FDA Refuse to File (RTF) Letter: In March 2025, Savara Pharmaceuticals submitted a Biologics License Application (BLA) to the U.S. FDA for Molgramostim in aPAP. However, in May 2025, the company announced that the FDA had issued a Refuse to File (RTF) letter.[7] An RTF letter is a procedural action indicating that the agency has determined the submitted application is not sufficiently complete to permit a substantive review. It effectively halts the review clock before it even begins.
• Nature of the Deficiency: The deficiencies identified by the FDA were specifically related to the Chemistry, Manufacturing, and Controls (CMC) section of the application.[7] This means the issues lie with the manufacturing process, quality control, product characterization, and stability data. Importantly, the FDA's letter did not raise any concerns regarding the clinical efficacy or safety data from the IMPALA-2 trial, nor did it request or recommend that the company conduct additional clinical studies.[7] This decisively pinpoints the problem to the technical, non-clinical aspects of the product's production and quality assurance.
• Company Response and Timeline: In response to the RTF, Savara announced its intention to request a meeting with the FDA to clarify the specific requirements. The company has publicly stated its confidence in its ability to address the agency's requests and has projected that it will be able to resubmit the BLA in the fourth quarter of 2025.[7] To mitigate future manufacturing risks and bolster its supply chain, the company is also in the process of establishing an alternative manufacturing pathway with an outsourcing partner.[42]

The issuance of an RTF letter based on CMC deficiencies represents a pivotal and defining challenge for the Molgramostim program. It fundamentally shifts the primary risk profile of the asset. Prior to the RTF, the key question was whether the drug would prove effective and safe in a large Phase 3 trial—a question that was answered with a resounding "yes." The risk was clinical. Now, the clinical success is established, but the program is stalled by technical hurdles. The central question has become whether the company can manufacture the drug-device combination product to the exacting standards of consistency, purity, and quality required by the FDA and provide the necessary documentation to prove it. This introduces a significant delay of at least a year and adds substantial operational and financial pressure. However, because the challenges are technical rather than clinical, they are generally considered solvable. The successful resolution of these CMC issues and the acceptance of the resubmitted BLA for review is now the single most critical near-term milestone for the program.

Section 7: Regulatory Trajectory and Market Outlook

This section will chart the drug's journey through the regulatory process and assess its future potential as a commercial product.

7.1. Global Regulatory Designations

Recognizing the high unmet medical need in aPAP and the promising clinical data for Molgramostim, regulatory agencies around the world have granted the program several special designations designed to expedite its development and review.

• U.S. Food and Drug Administration (FDA): Molgramostim has received a trio of important designations in the U.S.:
• Orphan Drug Designation: For rare diseases affecting fewer than 200,000 people in the U.S..[22]
• Fast Track Designation: To facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.[22]
• Breakthrough Therapy Designation: For a drug intended to treat a serious condition where preliminary clinical evidence indicates it may demonstrate substantial improvement over available therapy.[20]
• European Medicines Agency (EMA): The EMA has granted Orphan Drug Designation for Molgramostim for the treatment of aPAP.[22]
• UK Medicines and Healthcare products Regulatory Agency (MHRA): In the United Kingdom, the drug has received both the Innovative Passport and Promising Innovative Medicine (PIM) designations under the Innovative Licensing and Access Pathway (ILAP).[20]

These designations collectively signal a strong consensus among major global regulators that aPAP is a serious condition with inadequate treatment options and that Molgramostim represents a potentially significant therapeutic advance.

7.2. U.S. FDA Review and Expanded Access Program (EAP)

The regulatory journey in the U.S. has been marked by both strong support for the drug's clinical potential and a strict stance on its manufacturing standards.

• BLA Submission and RTF: As previously detailed, the BLA was submitted in March 2025, but received an RTF letter in May 2025 due to CMC deficiencies. A resubmission is planned for the fourth quarter of 2025.[7]
• Expanded Access Program (EAP): In September 2024, prior to the initial BLA submission, Savara launched an EAP (also known as a compassionate use program), registered under NCT06546098.[8] This program was established to provide pre-approval access to Molgramostim for eligible patients with aPAP who are unable to participate in clinical trials.[43] The FDA reviewed the protocol for this program and allowed it to proceed.[43]
• Significance of the EAP: The FDA's decision to permit the EAP is a significant indicator of the agency's view of the drug's clinical profile. EAPs are typically reserved for investigational drugs that treat serious or life-threatening conditions for which no comparable alternative therapies exist. The allowance of the EAP, particularly in light of the highly positive IMPALA-2 data, serves as a strong implicit acknowledgment from the FDA of Molgramostim's favorable clinical benefit-risk profile and the high unmet need in the aPAP patient community.[43]

The regulatory narrative for Molgramostim is one of stark contrast. On one hand, the drug has received nearly every special designation available to expedite its path to patients, and the FDA has sanctioned its use on a compassionate basis through an EAP. This demonstrates a clear recognition of its clinical value. On the other hand, the agency has enforced a hard stop on the review process due to a failure to meet the required technical standards for manufacturing and quality. This illustrates the two fundamental and non-negotiable pillars of drug approval: robust clinical evidence and unimpeachable manufacturing quality. Molgramostim has successfully cleared the first hurdle but has stumbled on the second. The EAP serves as a critical bridge during the ensuing regulatory delay, maintaining engagement with the patient and physician communities and providing continued access for those in need.

7.3. Future Commercial Prospects

Should the CMC issues be resolved and regulatory approval be granted, Molgramostim is positioned for a strong commercial launch.

• Market Position: As the first and only approved pharmacological therapy for aPAP in the U.S. and Europe, Molgramostim would immediately become the standard of care.[20] This first-mover advantage in a rare disease market with no existing competitors is a powerful commercial position.
• Revenue Potential: The combination of its novel inhaled biologic nature, its orphan drug status (which provides market exclusivity), and its potential to command premium pricing for a rare disease suggests that Molgramostim could generate a long-term, durable revenue stream for its developer.[30]

Section 8: Expert Synthesis and Future Directions

This final section provides a holistic assessment of Molgramostim, integrating all the preceding analyses into a concluding perspective and outlook.

8.1. Integrated Benefit-Risk Assessment

A comprehensive evaluation of Molgramostim reveals a highly favorable clinical profile that is currently overshadowed by technical and regulatory challenges.

• Benefit: The clinical benefits of inhaled Molgramostim for patients with aPAP are substantial, statistically robust, and clinically meaningful. The evidence from the pivotal IMPALA-2 trial is compelling, demonstrating significant improvements in the physiological function of the lungs (DLco%), patient-reported quality of life (SGRQ), and functional exercise capacity (peak METs). Furthermore, it addresses the disease at its source by reducing surfactant burden and, as a result, diminishes the need for the invasive WLL procedure.
• Risk: From a clinical standpoint, the risks associated with Molgramostim appear minimal. The therapy is well-tolerated, with a safety profile characterized by mild to moderate adverse events and exceptionally low rates of discontinuation. The inhaled route of administration successfully limits systemic exposure, mitigating the potential for more serious systemic side effects. The primary risks to the program at this juncture are not clinical but are instead regulatory and operational, centered entirely on the unresolved CMC deficiencies that must be addressed to the FDA's satisfaction.
• Conclusion: The clinical benefit-risk balance for Molgramostim in the treatment of aPAP is overwhelmingly positive. The current risk profile of the overall program is dominated by the manufacturing and regulatory uncertainty, which represents the sole remaining barrier to approval.

8.2. Concluding Remarks and Unmet Needs

Molgramostim stands as a testament to the potential of precision medicine and represents a potential paradigm shift in the management of autoimmune Pulmonary Alveolar Proteinosis. Its development showcases a therapeutic strategy that moves beyond symptomatic relief to target the fundamental pathophysiology of a disease. If approved, it will transform the treatment landscape for aPAP, replacing an invasive, burdensome, and periodic hospital-based procedure with a self-administered, chronic inhaled therapy that allows for long-term disease management.

The journey of Molgramostim, with its success in aPAP contrasted with its more limited utility in other respiratory diseases, highlights the power of developing targeted therapies for immunologically-defined patient populations. The final, and most critical, hurdle lies in the domain of manufacturing. The successful resolution of the CMC issues cited by the FDA is the critical path forward. Navigating this challenge will be essential to unlock the immense clinical and commercial value of Molgramostim and, most importantly, to deliver a long-awaited and much-needed therapeutic innovation to the aPAP patient community. Future research will likely focus on establishing the drug's long-term safety and efficacy, exploring its use in pediatric populations, and refining its optimal place within the aPAP treatment algorithm.

Works cited

1. Molbreevi (molgramostim) dosing, indications, interactions, adverse effects, and more, accessed September 26, 2025, https://reference.medscape.com/drug/molbreevi-molgramostim-4000544
2. Molgramostim Completed Phase 2 Trials for Mycobacterium Infections, Nontuberculous Treatment | DrugBank Online, accessed September 26, 2025, https://go.drugbank.com/drugs/DB12525/clinical_trials?conditions=DBCOND0051751&phase=2&purpose=treatment&status=completed
3. Molgramostim: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 26, 2025, https://go.drugbank.com/drugs/DB12525
4. CAS 99283-10-0: Molgramostim | CymitQuimica, accessed September 26, 2025, https://cymitquimica.com/cas/99283-10-0/
5. Savara Pharmaceuticals - Molgramostim - AdisInsight - Springer, accessed September 26, 2025, https://adisinsight.springer.com/drugs/800042679
6. 99283-10-0(MOLGRASTIM) Product Description - ChemicalBook, accessed September 26, 2025, https://www.chemicalbook.com/ChemicalProductProperty_US_CB5367630.aspx
7. FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset, accessed September 26, 2025, https://www.fiercepharma.com/manufacturing/fda-calls-additional-manufacturing-data-refusal-review-savaras-beleaguered
8. Study Details | NCT06546098 | Molgramostim Nebulizer Solution Expanded Access Program Protocol | ClinicalTrials.gov, accessed September 26, 2025, https://www.clinicaltrials.gov/study/NCT06546098?term=savara&rank=1
9. Molgramostim Nebulizer Solution Expanded Access Program Protocol - ClinicalTrials.Veeva, accessed September 26, 2025, https://ctv.veeva.com/study/molgramostim-nebulizer-solution-expanded-access-program-protocol
10. Molgramostim CRS | CAS Number 99283-10-0 - Klivon, accessed September 26, 2025, https://www.klivon.com/product/99283-10-0--molgramostim-crs
11. KEGG DRUG: Molgramostim - (www.genome.jp)., accessed September 26, 2025, https://www.genome.jp/dbget-bin/www_bget?D05066
12. MOLGRAMOSTIM - precisionFDA, accessed September 26, 2025, https://precision.fda.gov/ginas/app/ui/substances/83509196-8cee-4f77-875c-03fe82d582c1
13. Construction of Recombinant Human GM-CSF and GM-CSF-ApoA-I ..., accessed September 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8152757/
14. Pharmacokinetics and pharmacodynamics of inhaled molgramostim in healthy people, accessed September 26, 2025, https://bmjopenrespres.bmj.com/content/12/1/e002832.full.pdf
15. SAFETY, TOLERABILITY, PHARMACOKINETICS AND ... - Savara Inc., accessed September 26, 2025, https://savarapharma.com/wp-content/themes/savara/pdf/scientific-poster-may-2016.pdf
16. Definition of molgramostim - NCI Drug Dictionary, accessed September 26, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/molgramostim
17. Experimental Treatments: Molgramostim - Bronchiectasis News Today, accessed September 26, 2025, https://bronchiectasisnewstoday.com/bronchiectasis-experimental-treatments/molgramostim/
18. Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats - PMC, accessed September 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6803744/
19. Full article: Inhaled molgramostim therapy for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP): a plain language summary of the IMPALA trial - Taylor & Francis Online, accessed September 26, 2025, https://www.tandfonline.com/doi/full/10.1080/21548331.2024.2367955
20. Savara Reports Positive Phase 3 Results for Molgramostim in Rare Lung Disease, accessed September 26, 2025, https://globalgenes.org/raredaily/savara-reports-positive-phase-3-results-for-molgramostim-in-rare-lung-disease/
21. Molgramostim Reduces Surfactant Burden and Number of Whole Lung Lavage Procedures in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results From the IMPALA-2 Phase 3 Clinical Trial - ATS Journals, accessed September 26, 2025, https://www.atsjournals.org/doi/abs/10.1164/ajrccm.2025.211.Abstracts.A1129
22. Molgramostim Nebulizer Solution in aPAP | In Develoment - Savara Inc., accessed September 26, 2025, https://savarapharma.com/development/molgramostim-in-apap/
23. Pharmacokinetics and pharmacodynamics of inhaled molgramostim in healthy people, accessed September 26, 2025, https://bmjopenrespres.bmj.com/content/12/1/e002832
24. Pharmacokinetics and pharmacodynamics of inhaled molgramostim in healthy people, accessed September 26, 2025, https://pubmed.ncbi.nlm.nih.gov/40973220/
25. aPAP Clinical Trial Information For Patients - IMPALA-2, accessed September 26, 2025, https://www.impala2.com/patients/
26. New England Journal of Medicine (NEJM) to Publish ... - Savara Inc., accessed September 26, 2025, https://investors.savarapharma.com/news/news-details/2025/New-England-Journal-of-Medicine-NEJM-to-Publish-Results-From-Savaras-Pivotal-Phase-3-IMPALA-2-Clinical-Trial-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx
27. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis, accessed September 26, 2025, https://pubmed.ncbi.nlm.nih.gov/40834301/
28. RCT Abstract - Inhaled molgramostim improves pulmonary gas exchange and respiratory health-related quality of life (HRQoL) in patients with autoimmune pulmonary alveolar proteinosis (aPAP): Results from IMPALA-2 - ERS Publications, accessed September 26, 2025, https://publications.ersnet.org/content/erj/64/suppl68/pa5626
29. A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis - Yale Medicine, accessed September 26, 2025, https://www.yalemedicine.org/clinical-trials/impala-2-1
30. Corporate Overview - Savara Inc., accessed September 26, 2025, https://savarapharma.com/wp-content/uploads/SavaraCorporateDeck-June23-2023-FINAL.pdf
31. Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis | Clinical Research Trial Listing - CenterWatch, accessed September 26, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT02702180/efficacy-and-safety-of-inhaled-molgramostim-rhgm-csf-in-autoimmune-pulmonary-alveolar-proteinosis
32. OPTIMA: An Open-Label, Noncomparative Pilot Trial of Inhaled Molgramostim in Pulmonary Nontuberculous Mycobacterial Infection | Annals of the American Thoracic Society - ATS Journals, accessed September 26, 2025, https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202306-532OC
33. Safety and Tolerability of Inhaled Molgramostim in ... - Savara Inc., accessed September 26, 2025, https://savarapharma.com/wp-content/uploads/safety-and-tolerability.pdf
34. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis - PubMed, accessed September 26, 2025, https://pubmed.ncbi.nlm.nih.gov/32897035/
35. go.drugbank.com, accessed September 26, 2025, https://go.drugbank.com/drugs/DB12525#:~:text=Diphenhydramine-,The%20risk%20or%20severity%20of%20methemoglobinemia%20can%20be,Molgramostim%20is%20combined%20with%20Diphenhydramine.&text=Dyclonine-,The%20risk%20or%20severity%20of%20methemoglobinemia%20can%20be,Molgramostim%20is%20combined%20with%20Dyclonine.&text=Erythropoietin-,The%20risk%20or%20severity%20of%20Thrombosis%20can%20be,Erythropoietin%20is%20combined%20with%20Molgramostim.
36. Clinical Trial Protocol - ClinicalTrials.gov, accessed September 26, 2025, https://cdn.clinicaltrials.gov/large-docs/80/NCT02702180/Prot_000.pdf
37. Molgramostim - Uses, Dosage, Side Effects, Price, Composition | Practo, accessed September 26, 2025, https://www.practo.com/medicine-info/molgramostim-2640-api
38. Protein Expression in E. coli: A Powerful System for Recombinant Protein Production, accessed September 26, 2025, https://www.sinobiological.com/resource/protein-review/ecoli-protein-expression-system
39. New tools for recombinant protein production in Escherichia coli: A 5‐year update - PMC, accessed September 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6635841/
40. Protein Expression in E. Coli - NEB, accessed September 26, 2025, https://www.neb.com/en/applications/protein-expression/protein-expression-in-e-coli
41. Expression of proteins in E coli - QIAGEN, accessed September 26, 2025, https://www.qiagen.com/us/knowledge-and-support/knowledge-hub/bench-guide/protein/protein-expression-and-purification/expression-of-proteins-in-e-coli
42. Manufacturing issues scupper Savara's lead drug filing - pharmaphorum, accessed September 26, 2025, https://pharmaphorum.com/news/manufacturing-issues-scupper-savaras-lead-drug-filing
43. Savara Announces Expanded Access Program (EAP ... - Savara Inc., accessed September 26, 2025, https://investors.savarapharma.com/news/news-details/2024/Savara-Announces-Expanded-Access-Program-EAP-for-Molgramostim-Inhalation-Solution-Molgramostim-for-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-aPAP-09-27-2024/default.aspx
44. Pulmonary Alveolar Proteinosis, Autoimmune Available Phase Trials for Molgramostim (DB12525) | DrugBank Online, accessed September 26, 2025, https://go.drugbank.com/indications/DBCOND0085261/clinical_trials/DB12525?phase=&status=available
45. Molgramostim Nebulizer Solution Expanded Access Program Protocol - UCLA Health, accessed September 26, 2025, https://www.uclahealth.org/clinical-trials/molgramostim-nebulizer-solution-expanded-access-program